VERVE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.41 USD | +4.23% |
|
+4.06% | -54.02% |
| 04-03 | Stifel Cuts Price Target on Verve Therapeutics to $40 From $56, Maintains Buy Rating | MT |
| 04-02 | Sector Update: Health Care Stocks Slide Late Afternoon | MT |
| Sales 2024 * | 13.01M 1.04B | Sales 2025 * | 10.02M 799M | Capitalization | 538M 42.88B |
|---|---|---|---|---|---|
| Net income 2024 * | -226M -18.02B | Net income 2025 * | -254M -20.25B | EV / Sales 2024 * | 7.54 x |
| Net cash position 2024 * | 440M 35.07B | Net cash position 2025 * | 204M 16.28B | EV / Sales 2025 * | 33.3 x |
| P/E ratio 2024 * |
-2.19
x | P/E ratio 2025 * |
-2.1
x | Employees | 255 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.38% |
More Fundamentals
* Assessed data
More news
Latest transcript on Verve Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +4.23% | ||
| 1 week | +4.06% | ||
| Current month | +6.66% | ||
| 1 month | -26.41% | ||
| 3 months | -41.78% | ||
| 6 months | -58.86% | ||
| Current year | -54.02% |
1 week
5.84
7.00
1 month
5.848.77
Current year
5.8419.34
1 year
5.8421.42
3 years
5.8478.00
5 years
5.8478.00
10 years
5.8478.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sekar Kathiresan
FOU | Founder | 52 | 31/12/17 |
Allison Dorval
DFI | Director of Finance/CFO | 48 | 28/11/21 |
Andrew Ashe
PSD | President | 57 | 31/07/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Burt Adelman
FOU | Founder | 71 | 31/12/17 |
Lonnel Coats
BRD | Director/Board Member | 58 | 07/08/22 |
Michael MacLean
BRD | Director/Board Member | 58 | 30/04/21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.13% | 2 M€ | -25.75% | ||
| 3.54% | 1 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/05/24 | 6.41 | +4.23% | 1,394,797 |
| 02/05/24 | 6.15 | +2.50% | 949,617 |
| 01/05/24 | 6 | -0.17% | 1,764,706 |
| 30/04/24 | 6.01 | -3.99% | 1,022,039 |
| 29/04/24 | 6.26 | +1.62% | 933,216 |
Delayed Quote Nasdaq, May 03, 2024 at 09:30 pm
More quotes
Verve Therapeutics, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing a new approach to the care of cardiovascular disease (CVD), transforming treatment from chronic management to single-course gene editing medicines. The Companyâs lead programs include VERVE-101, VERVE-102, and VERVE-201, which target genes that have been validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH). VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for homozygous familial hypercholesterolemia (HoFH) and for refractory hypercholesterolemia where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies.
Calendar
06/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
6.41
USD
Average target price
31.22
USD
Spread / Average Target
+387.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -54.02% | 516M | |
| +25.69% | 48.09B | |
| +46.90% | 40.62B | |
| -3.46% | 40.43B | |
| -6.20% | 28.36B | |
| +9.17% | 24.89B | |
| -20.42% | 19.01B | |
| +28.07% | 12.09B | |
| +0.17% | 11.88B | |
| -1.24% | 11.8B |
- Stock Market
- Equities
- VERV Stock
